Rights and permissions
About this article
Cite this article
Mercaptopurine favoured over mesalazine for patients with Crohn's disease that relapse within 3 months of surgery. Pharmacoecon. Outcomes News 322, 5–6 (2001). https://doi.org/10.1007/BF03269494
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03269494